About AVT
Browse Articles
Authors
Customer Services

Original article

Estimated average annual rate of change of CD4+ T-cell counts in patients on combination antiretroviral therapy

Amanda Mocroft, Andrew N Phillips, Bruno Ledergerber, Colette Smith, Johannes R Bogner, Karine Lacombe, Alicje Wiercinska-Drapalo, Peter Reiss, Ole Kirk, Jens D Lundgren, the EuroSIDA Study Group

Corresponding author name: Amanda Mocroft
Corresponding author e-mail: a.mocroft@ucl.ac.uk

Citation: Antiviral Therapy 2010; 15:563-570
doi: 10.3851/IMP1559

Date accepted: 07 December 2009
Date published online: 11 June 2010

Abstract

Background: Patients receiving combination antiretroviral therapy (cART) might continue treatment with a virologically failing regimen. We sought to identify annual change in CD4+ T-cell count according to levels of viraemia in patients on cART.

Methods: A total of 111,371 CD4+ T-cell counts and viral load measurements in 8,227 patients were analysed. Annual change in CD4+ T-cell numbers was estimated using mixed models.

Results: After adjustment, the estimated average annual change in CD4+ T-cell count significantly increased when viral load was <500 copies/ml (30.4 cells/mm3, 95% confidence interval [CI] 26.6–34.3), was stable when viral load was 500–9,999 copies/ml (3.1 cells/mm3, 95% CI -5.3–11.5) and decreased when viral load was ≥10,000 copies/ml (-14.8 cells/mm3, 95% CI -4.5–-25.1). Patients taking a boosted protease inhibitor (PI) regimen had more positive annual CD4+ T-cell count changes than patients taking other regimens for any given viral load strata: 30.9 cells/mm3 (95% CI 27.7–34.1) when viral load was <500 copies/ml, 14.2 cells/mm3 (95% CI -2.1–30.4) when viral load was 500–9,999 copies/ml and -19.9 cells/mm3 (95% CI -36.6–-3.3) when viral load was ≥10,000 copies/ml. By contrast, among patients taking a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen, the CD4+ T-cell count significantly decreased when the viral load was 500–9,999 copies/ml (-18.6 cells/mm3, 95% CI -33.8–-3.5) and decreased at a faster rate when the viral load was ≥10,000 copies/ml (-44.4 cells/mm3, 95% CI -62.0–-26.9; P=0.0012, test for interaction).

Conclusions: On average, CD4+ T-cell counts did not significantly decrease until the viral load exceeded 10,000 copies/ml in patients treated with a boosted PI-containing cART regimen, but decreased in patients taking an NNRTI-based cART regimen when viral load was 500–9,999 copies/ml.

<< BACK

Copyright © Nucleus Global 2017. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.